2025
Integrated Immune Landscape Analysis of RNA Splicing Factor-Mutant AML and Higher risk MDS Treated with Azacitidine ± Durvalumab
Bewersdorf J, Hasle V, Shallis R, Thompson E, de Menezes D, Rose S, Boss I, Mendez L, Podoltsev N, Stahl M, Kewan T, Halene S, Haferlach T, Fox B, Zeidan A. Integrated Immune Landscape Analysis of RNA Splicing Factor-Mutant AML and Higher risk MDS Treated with Azacitidine ± Durvalumab. Therapeutic Advances In Hematology 2025, 16: 20406207251347344. PMID: 40546817, PMCID: PMC12182606, DOI: 10.1177/20406207251347344.Peer-Reviewed Original ResearchThis study investigates the immune landscape of RNA splicing factor-mutant AML and MDS, showing no survival benefit from adding durvalumab to azacitidine treatment.
2021
Airway microbiome dynamics and relationship to ventilator‐associated infection in intubated pediatric patients
Tarquinio KM, Karsies T, Shein SL, Beardsley A, Khemani R, Schwarz A, Smith L, Flori H, Karam O, Cao Q, Haider Z, Smirnova E, Serrano MG, Buck GA, Willson DF. Airway microbiome dynamics and relationship to ventilator‐associated infection in intubated pediatric patients. Pediatric Pulmonology 2021, 57: 508-518. PMID: 34811963, PMCID: PMC8809006, DOI: 10.1002/ppul.25769.Peer-Reviewed Original ResearchConceptsVentilator-associated infectionDays of intubationAirway microbiomeSerial tracheal aspirate samplesPediatric intensive care unitIntensive care unitIntubated pediatric patientsTracheal aspirate samplesTracheal microbiomePediatric patientsCare unitClinical parametersIntubation periodClinical variablesAntibiotic treatmentVentilated subjectsAspirate samplesInfection scoreMedian numberSubject demographicsPorphyromonadaceae familyMicrobiome patternsIntubationVeillonella atypicaPatientsSensitive and Feasible Specimen Collection and Testing Strategies for Diagnosing Tuberculosis in Young Children
Song R, Click ES, McCarthy KD, Heilig CM, Mchembere W, Smith JP, Fajans M, Musau SK, Okeyo E, Okumu A, Orwa J, Gethi D, Odeny L, Lee SH, Perez-Velez CM, Wright CA, Cain KP. Sensitive and Feasible Specimen Collection and Testing Strategies for Diagnosing Tuberculosis in Young Children. JAMA Pediatrics 2021, 175: e206069. PMID: 33616611, PMCID: PMC7900937, DOI: 10.1001/jamapediatrics.2020.6069.Peer-Reviewed Original ResearchConceptsGastric aspiratesNPA samplesResource-limited settingsCurrent reference standardDiagnostic yieldTuberculosis diagnosisXpert MTB/RIFCross-sectional diagnostic studyReference standardNasopharyngeal aspirate samplesSymptoms of tuberculosisMycobacteria growth indicator tube (MGIT) cultureMTB/RIFIncremental diagnostic yieldPositive test resultsYoung childrenSpecimen typesInvasive specimenCervical lymphadenopathyMedian ageMycobacterium tuberculosis complexParenchymal abnormalitiesConsecutive seriesOutpatient settingAspirate samples
2019
Identification of new biomarkers of bronchopulmonary dysplasia using metabolomics
Piersigilli F, Lam TT, Vernocchi P, Quagliariello A, Putignani L, Aghai ZH, Bhandari V. Identification of new biomarkers of bronchopulmonary dysplasia using metabolomics. Metabolomics 2019, 15: 20. PMID: 30830433, DOI: 10.1007/s11306-019-1482-9.Peer-Reviewed Original ResearchConceptsBronchopulmonary dysplasiaPreterm neonatesNew biomarkersNeonatal intensive care unitMost preterm infantsIntensive care unitNovel specific biomarkersTracheal aspirate samplesSub-group analysisGestational age differencesPreterm infantsCare unitAspirate samplesNeonatesSpecific biomarkersFirst weekC16-OHIsoleucine levelsSelect metabolitesBiomarkersDysplasiaPartial least squares discriminant analysisLeast squares discriminant analysisSquares discriminant analysisAge differences
1989
Multipolar electrocoagulation in the treatment of peptic ulcers with nonbleeding visible vessels. A prospective, controlled trial.
Laine L. Multipolar electrocoagulation in the treatment of peptic ulcers with nonbleeding visible vessels. A prospective, controlled trial. Annals Of Internal Medicine 1989, 110: 510-4. PMID: 2647014, DOI: 10.7326/0003-4819-110-7-510.Peer-Reviewed Original ResearchConceptsNonbleeding visible vesselMultipolar electrocoagulationVisible vesselControl groupMajor upper gastrointestinal hemorrhageMean transfusion requirementSham-controlled trialUpper gastrointestinal hemorrhageUnstable vital signsSafety of treatmentCost of hospitalizationUnits of bloodEndoscopic evidenceGastrointestinal hemorrhageTransfusion requirementsUrgent surgeryEmergency surgeryHospital daysEndoscopic treatmentOverall mortalityPeptic ulcerCounty HospitalAspirate samplesDiagnostic endoscopyTreatment groups
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply